Fig. 3From: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancerThe effect of gemcitabine on immunomodulatory plasma proteins. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 29 always before gemcitabine was given that day. Plasma levels of Arginase-1, MPO and TGFβ-1 were evaluated by ELISA (a–c) and MDS multiplex analysis was performed for determining plasma levels of IL-1β, IL-6, IL-8, IL-10 and TNFα (d–h). Concentrations are displayed in ng/mL or pg/mL and statistical differences were assessed by Wilcoxon matched-pairs signed-rank test (*P < 0.05, ** P < 0.01)Back to article page